RPAM
CNTA

Rhenman & Partners Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$2.5M – 92
2025
Q4 		$2.5M Buy
+100,000
New +$2.53M 0.23% 85

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Rhenman & Partners Asset Management's CNTA Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 100,000 shares — an estimated $2.5M sold.

Rhenman & Partners Asset Management first reported a position in CNTA in Q4 2025 and held it in 1 quarter. The position peaked at $2.5M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Rhenman & Partners Asset Management reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 100,000 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2.5M.
  • Rhenman & Partners Asset Management first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Centessa Pharmaceuticals position peaked at $2.5M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.